Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Clinical utility of low-pressure implantation of drug-eluting stent into very small vessels.

Suga T, Iwanaga Y, Kobuke K, Morimoto K, Ikuta S, Ueno M, Kobayashi N, Yamaji K, Ikeda T, Miyazaki S.

J Cardiol. 2014 Mar;63(3):218-22. doi: 10.1016/j.jjcc.2013.08.006.

2.

A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).

Ribichini F, Romano M, Rosiello R, La Vecchia L, Cabianca E, Caramanno G, Milazzo D, Loschiavo P, Rigattieri S, Musarò S, Pironi B, Fiscella A, Amico F, Indolfi C, Spaccarotella C, Bartorelli A, Trabattoni D, Della Rovere F, Rolandi A, Beqaraj F, Belli R, Sangiorgio P, Villani R, Berni A, Sheiban I, Lopera Quijada MJ, Cappi B, Ribaldi L, Vassanelli C; EXECUTIVE Trial Investigators..

JACC Cardiovasc Interv. 2013 Oct;6(10):1012-22. doi: 10.1016/j.jcin.2013.05.016.

3.

Direct drug-eluting stenting to reduce stent restenosis: a randomized comparison of direct stent implantation to conventional stenting with pre-dilation or provisional stenting in elective PCI patients.

Remkes WS, Somi S, Roolvink V, Rasoul S, Ottervanger JP, Gosselink AT, Hoorntje JC, Dambrink JH, de Boer MJ, Suryapranata H, van 't Hof AW; Acute Myocardial Infarction Study Group..

JACC Cardiovasc Interv. 2014 Jul;7(7):751-8. doi: 10.1016/j.jcin.2014.02.012.

4.
5.

Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.

Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E.

Arch Cardiovasc Dis. 2013 Nov;106(11):554-61. doi: 10.1016/j.acvd.2013.06.056.

6.

Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.

Tiroch K, Mehilli J, Byrne RA, Schulz S, Massberg S, Laugwitz KL, Vorpahl M, Seyfarth M, Kastrati A; ISAR-LEFT MAIN Study Investigators..

JACC Cardiovasc Interv. 2014 Jan;7(1):29-36. doi: 10.1016/j.jcin.2013.08.013.

7.

Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.

Liistro F, Porto I, Angioli P, Grotti S, Ducci K, Falsini G, Bolognese L.

Am Heart J. 2013 Nov;166(5):920-6. doi: 10.1016/j.ahj.2013.08.023.

PMID:
24176449
8.

First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).

Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W.

JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013.

9.

Usefulness of intravascular ultrasound to predict outcomes in short-length lesions treated with drug-eluting stents.

Yoon YW, Shin S, Kim BK, Kim JS, Shin DH, Ko YG, Choi D, Jeon DW, Kwon H, Jang Y, Hong MK; RESET Investigators..

Am J Cardiol. 2013 Sep 1;112(5):642-6. doi: 10.1016/j.amjcard.2013.04.037.

PMID:
23711810
10.

Repeat drug-eluting stent implantation for in-stent restenosis: first- or second-generation stent.

Yamashita K, Ochiai M, Yakushiji T, Ebara S, Okabe T, Yamamoto MH, Saito S, Hoshimoto K, Isomura N, Araki H, Obara C.

J Invasive Cardiol. 2012 Nov;24(11):574-8.

11.

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis.

Nojima Y, Yasuoka Y, Kume K, Adachi H, Hattori S, Matsutera R, Kohama Y, Sasaki T.

Coron Artery Dis. 2014 Dec;25(8):638-44. doi: 10.1097/MCA.0000000000000159.

12.

Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.

Loh JP, Stella PR, Sangiorgi G, Silber S, Stahnke S, von Strandmann RP, Torguson R, Waksman R.

Cardiovasc Revasc Med. 2014 Jan;15(1):23-8. doi: 10.1016/j.carrev.2013.08.011.

PMID:
24444473
13.

Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH).

Valgimigli M, van Mieghem CA, Ong AT, Aoki J, Granillo GA, McFadden EP, Kappetein AP, de Feyter PJ, Smits PC, Regar E, Van der Giessen WJ, Sianos G, de Jaegere P, Van Domburg RT, Serruys PW.

Circulation. 2005 Mar 22;111(11):1383-9.

14.

Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.

Chen SL, Ye F, Zhang JJ, Zou JJ, Qian XS, Li F, Yang S, Ge Z, Shan SJ, Li XB, Xu T, Kan J, Lin L, Han YL.

Cardiovasc Ther. 2013 Aug;31(4):193-200. doi: 10.1111/j.1755-5922.2012.00319.x.

PMID:
22954234
15.

Characteristics of patients and types of lesions in patients with drug-eluting or bare-metal stent implantation in small coronary arteries: from the FU-Registry.

Sugihara M, Miura S, Nishikawa H, Ike A, Mori K, Iwata A, Kawamura A, Saku K.

J Cardiol. 2013 Feb;61(2):117-21. doi: 10.1016/j.jjcc.2012.09.008.

16.

Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]).

Alfonso F, Pérez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, García-Touchard A, Martí V, Lozano I, Angel J, Hernández JM, López-Mínguez JR, Melgares R, Moreno R, Seidelberger B, Fernández C, Hernandez R; RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology)..

JACC Cardiovasc Interv. 2012 Jul;5(7):728-37. doi: 10.1016/j.jcin.2012.03.017.

17.

Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.

Mirabella F, Francaviglia B, Capodanno D, Di Salvo ME, Galassi AR, Ussia GP, Capranzano P, Tamburino C.

J Invasive Cardiol. 2009 Apr;21(4):145-50.

PMID:
19342750
18.

Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation.

Gao RL, Xu B, Chen JL, Yang YJ, Qiao SB, Li JJ, Qin XW, Yao M, Liu HB, Wu YJ, Yuan JQ, Chen J.

Am Heart J. 2008 Mar;155(3):553-61. doi: 10.1016/j.ahj.2007.10.030.

PMID:
18294496
19.

Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results.

Rodriguez A, Rodríguez Alemparte M, Fernández Pereira C, Sampaolesi A, da Rocha Loures Bueno R, Vigo F, Obregón A, Palacios IF; LASMAL investigators..

Am J Med. 2005 Jul;118(7):743-51.

PMID:
15989908
20.

Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.

Abdel-Wahab M, Baev R, Dieker P, Kassner G, Khattab AA, Toelg R, Sulimov D, Geist V, Richardt G.

Catheter Cardiovasc Interv. 2013 Feb;81(2):285-91. doi: 10.1002/ccd.24367.

PMID:
22431433
Items per page

Supplemental Content

Support Center